Nieva also discussed the ROS1 fusion partner subgroup. Whether the partner was CD74 or another gene, the overall response ...

Fast track designation targets a post–immunotherapy and post-platinum KRAS G12C–mutant NSCLC population, enabling closer FDA ...

FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus ...

Andrew Kuykendall, MD, discusses where rusfertide (Mimrylo) may fit within the treatment paradigm for polycythemia vera and ...

Giada Bianchi, MD, discusses tailoring therapy in myeloma, addressing ultra-high-risk disease, and amyloidosis becoming a ...

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty. In this episode of The ...

Ubamatamab redirects T cells via CD3 engagement to MUC16-expressing tumor cells, leveraging uniformly high MUC16 expression in LGSOC and enabling responses without molecular preselection. At 800 mg ...

Out-of-pocket costs drove abandonment: fill rates fell from ~80% at ≤$15 to ~30% at $500–$2000, and to 21.6% when >$2000 commercially. Prior authorization dominated rejection reasons (32.1% Medicare; ...

In this segment, Dr. Luciano Costa provides practical considerations for managing patients with newly diagnosed multiple ...

In this segment, Dr. Peter Voorhees and Dr. Doris Hansen discuss the safety profile and post-treatment management of CAR ...

Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to ...